Royal Bank of Canada
ABOS icon

Royal Bank of Canada’s Acumen Pharmaceuticals ABOS Stock Holding History

Royal Bank of Canada’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$17K Buy
7,090
+4,808
+211% +$12.3K ﹤0.01% 5960
2025
Q4 		$5K Buy
2,282
+1,162
+104% +$2.31K ﹤0.01% 6687
2025
Q3 		$2K Buy
1,120
+151
+16% +$209 ﹤0.01% 6851
2025
Q2 		$1K Sell
969
-7,571
-89% -$8.14K ﹤0.01% 6845
2025
Q1 		$9K Sell
8,540
-6,121
-42% -$8.74K ﹤0.01% 6179
2024
Q4 		$25K Buy
14,661
+8,720
+147% +$21K ﹤0.01% 6011
2024
Q3 		$15K Buy
5,941
+1,896
+47% +$5.14K ﹤0.01% 6189
2024
Q2 		$10K Buy
4,045
+3,943
+3,866% +$12.6K ﹤0.01% 6319
2024
Q1 		$0 Sell
102
-566
-85% -$2.13K ﹤0.01% 6940
2023
Q4 		$2K Buy
668
+566
+555% +$1.68K ﹤0.01% 6778
2023
Q3 		$0 Sell
102
-194
-66% -$1.2K ﹤0.01% 7017
2023
Q2 		$1K Sell
296
-88
-23% -$421 ﹤0.01% 6952
2023
Q1 		$2K Buy
384
+379
+7,580% +$1.98K ﹤0.01% 6744
2022
Q4 		$0 Sell
5
-46
-90% -$309 ﹤0.01% 7161
2022
Q3 		$1K Buy
+51
New +$293 ﹤0.01% 7134
2022
Q2 		– Sell
-1,739
Closed -$7K – 7314
2022
Q1 		$7K Sell
1,739
-631
-27% -$3.43K ﹤0.01% 7097
2021
Q4 		$16K Buy
2,370
+1,269
+115% +$13.9K ﹤0.01% 6879
2021
Q3 		$16K Buy
+1,101
New +$18.3K ﹤0.01% 6783

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Royal Bank of Canada's ABOS Position: Q1 2026 in Review

Royal Bank of Canada increased its Acumen Pharmaceuticals (ABOS) stake by 211% in Q1 2026, buying an estimated $12.3K and bringing the position to 7,090 shares worth $17K. The position accounts for ﹤0.01% of the portfolio, ranked #5960.

Royal Bank of Canada first reported a position in ABOS in Q3 2021 and has held it in 18 quarters since. The position peaked at $25K in Q4 2024. 84 funds tracked by Wall St. Rank hold ABOS as of Q1 2026.

  • Royal Bank of Canada held 7,090 shares of Acumen Pharmaceuticals worth $17K as of Q1 2026.
  • Royal Bank of Canada bought 4,808 Acumen Pharmaceuticals shares in Q1 2026, an estimated $12.3K.
  • Acumen Pharmaceuticals made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #5960 holding.
  • Royal Bank of Canada first reported a position in Acumen Pharmaceuticals in Q3 2021 and has held it in 18 quarters since.
  • Royal Bank of Canada's Acumen Pharmaceuticals position peaked at $25K in Q4 2024.
  • 84 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.